D&D Pharmatech said on April 16 it has signed a research service agreement with U.S. pharmaceutical company Pfizer for the development of an oral peptide dual agonist formulation for obesity treatment.
The contract is valued at approximately $1.24 million, equivalent to 42.64% of the company’s revenue from the previous year. The contract period runs through Nov. 30.
The agreement targets the U.S. market, and payment will be made within 90 days after completion of the contracted research services. No upfront or advance payments are included, and the project will be carried out through in-house production.
